GO
Loading...

Medicine

More

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • Ebola continues to rage in West Africa  Monday, 17 Nov 2014 | 10:09 AM ET

    Ebola patient Dr. Martin Salia has died from the virus. CNBC's Meg Tirrell discusses the need for better and faster Ebola diagnostics.

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • Intercept CEO: NASH epidemic of liver disease  Friday, 14 Nov 2014 | 3:16 PM ET

    Intercept Pharmaceuticals CEO Mark Pruzanski, provides insight to his company's efforts to tackle NASH, or nonalcoholic steatohepatitis, saying over 10 percent of the U.S. population is thought to have NASH. Pruzanski also weighs in on being a public company.

  • DAKAR/ BRUSSELS, Nov 14- Medecins Sans Frontiers "wasted time" by waiting too long to call for vaccines to fight an unprecedented outbreak of Ebola in West Africa, a veteran of the medical charity told Reuters. The group's response to the epidemic which has so far killed more than 5,000 people has been widely praised by governments and the World Health Organization.

  • Nov 13- Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading. Puma Biotech's founder and Chief Executive Alan Auerbach had also founded cancer drug developer Cougar Biotech which was sold to Johnson& Johnson for about 1 billion in 2009..

  • UK doctors to 'prescribe' health apps Thursday, 13 Nov 2014 | 8:31 AM ET

    UK patients could soon be "prescribed" a smartphone application instead of a medical prescription when visiting their doctor.

  • Cepheid receives grant to develop Ebola diagnostic test Thursday, 13 Nov 2014 | 7:50 AM ET

    Nov 13- Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill& Melinda Gates Foundation, to develop a diagnostic test for the deadly Ebola virus. The Xpert Ebola test, which is expected to use saliva or a drop of blood to identify the virus, is likely to be offered on an...

  • Why plastic bottles could be bad for your health Wednesday, 12 Nov 2014 | 10:45 AM ET

    Experts are meeting in Brussels to debate whether some materials like plastic bottles could be dangerous.

  • Nov 11- Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments. The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of...

  • Nov 11- AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat. AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

  • Hepatitis B next great challenge: Arrowhead  Monday, 10 Nov 2014 | 1:11 PM ET

    Chris Anzalone, Arrowhead CEO, discusses current studies on the hepatitis B virus and its effect on the liver, and whether the company is gaining the confidence back of shareholders.

  • Dendreon files bankruptcy protection  Monday, 10 Nov 2014 | 10:38 AM ET

    Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.

  • Big pharma's push to save your liver  Monday, 10 Nov 2014 | 7:32 AM ET

    CNBC's Meg Tirrell reports on the increasing competition among pharma companies for the fight against hepatitis C.

  • NEW YORK, Nov 9- Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on...

  • Robots can't catch Ebola  Friday, 7 Nov 2014 | 1:20 PM ET

    CNBC's Josh Lipton reports what specialists are learning about the capabilities of robotics in the fight against Ebola.

  • *Liberia has been hardest hit by regional epidemic. MONROVIA/ ABIDJAN, Nov 7- Health workers in Liberia are struggling to tell whether a growing number of empty beds at Ebola treatment centers is a sign that the country's ramped up response to the disease is working- or just a lull in the epidemic. The virus has killed nearly 5,000 people there and in neighboring...

  • Nov 4- Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Jefferies analysts in a note published on Oct. 20 said oncologists expect the drug to have little or no benefits in terms of overall survival. "Thus, FDA approval is unlikely in our view," they wrote.

  • BEIJING, Nov 4- China has contributed over $120 million to fight the spread of the Ebola virus, but its billionaire tycoons- it has more than anywhere outside the United States- have, publicly at least, donated little to the cause, underscoring an immature culture of philanthropy in the world's second-biggest economy. Many big Chinese companies have invested in...